Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
26 Results for "
RNA interference
" in MedChemExpress (MCE) Product Catalog:
Products (26)
26 Results for "RNA interference" in MCE Product Catalog:
1
Research Areas:
Nedosiran (DCR-PHXC) sodium is an RNA interference (RNAi) targeting lactate dehydrogenase (LDH). Nedosiran sodium represents an impactful potential therapeutic for primary hyperoxaluria (PH) with end-stage renal disease (ESRD). Nedosiran sodium is a GalNAc-dsRNA conjugate .
1
1 Cited Publications
Research Areas:
Lumasiran sodium, an investigational RNA interference (RNAi) therapeutic agent, reduces hepatic oxalate production by targeting glycolate oxidase. Lumasiran sodium reduces urinary oxalate excretion, the cause of progressive kidney failure in primary hyperoxaluria type 1 (PH1) .
1
1 Cited Publications
Research Areas:
98N12-5 is a lipid delivery material that assembles to form lipid nanoparticles and mediates the intracellular delivery of siRNA to hepatocytes . 98N12-5 is used in RNA interference-related research .
1
Research Areas:
Nedosiran (DCR-PHXC) is an RNA interference (RNAi) targeting lactate dehydrogenase (LDH). Nedosiran represents an impactful potential therapeutic for primary hyperoxaluria (PH) with end-stage renal disease (ESRD). Nedosiran is a GalNAc-dsRNA conjugate .
Cat. No.: HY-147425
CAS No.: 2646703-64-0
Synonyms: SLN360
Research Areas:
Zerlasiran (SLN360) is a siRNA targeting apolipoprotein A (ApoA). Zerlasiran targets hepatic ApoA synthesis via RNA interference to degrade encoding mRNA. Zerlasiran can be used for the research of atherosclerotic cardiovascular disease and elevated ApoA levels .
Cat. No.: HY-164740
CAS No.: 2379776-40-4
Synonyms: ARO-APOC3
Research Areas:
Plozasiran (ARO-APOC3) is a siRNA targeting APOC3. Plozasiran mediates RNA interference-mediated degradation and silencing of APOC3 mRNA, reducing APOC3 synthesis and expression, apoC3 protein expression, and plasma ApoC3 concentrations. Plozasiran reduces fasting and non-fasting plasma triglyceride concentrations in diet-induced hypertriglyceridemia. Plozasiran can be used in research on hypertriglyceridemia, mixed hyperlipidemia, and mixed dyslipidemia .
Synonyms: DAQ B1; L-783281; Dimethylasterriquinone
Target:
Insulin Receptor Akt NO Synthase NADPH Oxidase JAK STAT FOXO DNA/RNA Synthesis ERK Flavivirus
Research Areas:
Cardiovascular Disease Infection Metabolic Disease Inflammation/Immunology
Demethylasterriquinone B1 (DAQ B1; L-783281) is an orally active insulin receptor (insulin receptor) agonist and AKT activator. By activating AKT, Demethylasterriquinone B1 upregulates the expression and activity of eNOS to increase NO production, while downregulating the expression of the NADPH oxidase subunit p22phox to reduce oxidative stress and improve vascular endothelial dysfunction in hypertensive rats. Demethylasterriquinone B1 combind with an AKT inhibitor targets the insulin signaling pathway to activate two antiviral pathways, RNA interference and JAK/STAT, in mosquitoes, thereby reducing Zika virus infection .
Cat. No.: HY-145720
CAS No.: 1639264-46-2
Synonyms: ALN-CC5
Research Areas:
Cemdisiran (ALN-CC5) is an N-acetylgalactosamine-conjugated RNAi agent and also a complement component C5 inhibitor. Cemdisiran targets C5 mRNA, cleaves C5 mRNA via the endogenous RNA interference pathway, and inhibits the production of C5 protein in the liver. Cemdisiran exerts a dose-dependent inhibitory effect on total C5 concentrations in cynomolgus monkeys. When used in combination with Pozelimab (HY-P99786) in cynomolgus monkeys, Cemdisiran achieves a more sustained and complete inhibitory effect on complement activity. Cemdisiran can be used in the research of paroxysmal nocturnal hemoglobinuria and other complement-mediated diseases .
Cat. No.: HY-147425A
Purity: 95.52%
Synonyms: SLN360 sodium
Research Areas:
Zerlasiran (SLN360) sodium is a siRNA targeting apolipoprotein A (ApoA). Zerlasiran sodium targets hepatic ApoA synthesis via RNA interference to degrade encoding mRNA. Zerlasiran sodium can be used for the research of atherosclerotic cardiovascular disease and elevated ApoA levels .
Cat. No.: HY-132590A
Purity: 93.16%
Synonyms: ALN-TTRSC sodium
Research Areas:
Revusiran (ALN-TTRSC) sodium is an RNA interference agent targeting the mRNA of transthyretin (Transthyretin, TTR). Revusiran sodium mediates sequence-specific degradation of TTR mRNA through RNA interference, reduces the synthesis of TTR protein, binds to GalNAc ligands, and is taken up by hepatocytes via the asialoglycoprotein receptor. Revusiran sodium exhibits favorable nonclinical safety profiles. Revusiran sodium can be used in studies related to transthyretin-mediated amyloidosis .
Cat. No.: HY-164740A
CAS No.: 2379776-41-5
Synonyms: ARO-APOC3 sodium
Research Areas:
Plozasiran sodium (ARO-APOC3 sodium) is a siRNA targeting APOC3. Plozasiran sodium mediates RNA interference-mediated degradation and silencing of APOC3 mRNA, reducing APOC3 synthesis and expression, apoC3 protein expression, and plasma ApoC3 concentrations. Plozasiran sodium reduces fasting and non-fasting plasma triglyceride concentrations in diet-induced hypertriglyceridemia. Plozasiran sodium can be used in research on hypertriglyceridemia, mixed hyperlipidemia, and mixed dyslipidemia .
Cat. No.: HY-153484A
CAS No.: 849758-52-7
Target:
Research Areas:
Bevasiranib sodium is a siRNA that targets and silences VEGF-A. Bevasiranib sodium activates the RNA-induced silencing complex to degrade VEGF-A mRNA, mediates TLR3-related inhibition of choroidal neovascularization, and triggers RNA interference-mediated gene silencing through endogenous eukaryotic RNAi mechanisms. After intravitreal injection, Bevasiranib sodium distributes to various ocular tissues and resists degradation by intraocular nucleases, reducing choroidal neovascularization area and alleviating vascular leakage. Bevasiranib sodium can be used in research related to macular degeneration .
Cat. No.: HY-145720A
Purity: 96.02%
Synonyms: ALN-CC5 sodium
Research Areas:
Cemdisiran sodium (ALN-CC5 sodium) is an N-acetylgalactosamine-conjugated RNAi agent and also a complement component C5 inhibitor. Cemdisiran sodium targets C5 mRNA, cleaves C5 mRNA via the endogenous RNA interference pathway, and inhibits the production of C5 protein in the liver. Cemdisiran sodium exerts a dose-dependent inhibitory effect on total C5 concentrations in cynomolgus monkeys. When used in combination with Pozelimab (HY-P99786) in cynomolgus monkeys, Cemdisiran sodium achieves a more sustained and complete inhibitory effect on complement activity. Cemdisiran sodium can be used in the research of paroxysmal nocturnal hemoglobinuria and other complement-mediated diseases .
Cat. No.: HY-132590
CAS No.: 1438322-82-7
Synonyms: ALN-TTRSC
Research Areas:
Revusiran (ALN-TTRSC) is an RNA interference agent targeting the mRNA of transthyretin (Transthyretin, TTR). Revusiran mediates sequence-specific degradation of TTR mRNA through RNA interference, reduces the synthesis of TTR protein, binds to GalNAc ligands, and is taken up by hepatocytes via the asialoglycoprotein receptor. Revusiran exhibits favorable nonclinical safety profiles. Revusiran can be used in studies related to transthyretin-mediated amyloidosis .
Cat. No.: HY-145649
CAS No.: 2380166-33-4
Synonyms: AD-85481; ALN-AGT
Target:
Research Areas:
Zilebesiran is a siRNA that reduce hepatic angiotensinogen levels through RNA interference. it is used for the study of mild to moderate Hypertension. Angiotensinogen is the predominant precursor of angiotensin peptides and a key regulator of systemic blood pressure.
Cat. No.: HY-177646
CAS No.: 2572991-83-2
Synonyms: ALN-APP
Research Areas:
Mivelsiran (ALN-APP) is an siRNA targeting the β-amyloid precursor protein (APP). Mivelsiran induces sequence-specific degradation of APP mRNA via RNA interference, thereby reducing the levels of APP protein and downstream amyloid cleavage products. Mivelsiran reduces β-amyloid protein levels in the brain, alleviates neuroinflammation, and attenuates microglial proliferation. Mivelsiran can be used for research on early-onset Alzheimer's disease .
Cat. No.: HY-153484
CAS No.: 959961-96-7
Target:
Research Areas:
Bevasiranib is a siRNA that targets and silences VEGF-A. Bevasiranib activates the RNA-induced silencing complex to degrade VEGF-A mRNA, mediates TLR3-related inhibition of choroidal neovascularization, and triggers RNA interference-mediated gene silencing through endogenous eukaryotic RNAi mechanisms. After intravitreal injection, Bevasiranib distributes to various ocular tissues and resists degradation by intraocular nucleases, reducing choroidal neovascularization area and alleviating vascular leakage. Bevasiranib can be used in research related to macular degeneration .
Cat. No.: HY-177646A
Synonyms: ALN-APP sodium
Research Areas:
Mivelsiran (ALN-APP) sodium is an siRNA targeting the β-amyloid precursor protein (APP). Mivelsiran sodium induces sequence-specific degradation of APP mRNA via RNA interference, thereby reducing the levels of APP protein and downstream amyloid cleavage products. Mivelsiran sodium reduces β-amyloid protein levels in the brain, alleviates neuroinflammation, and attenuates microglial proliferation. Mivelsiran sodium can be used for research on early-onset Alzheimer's disease .
Cat. No.: HY-147425D
Synonyms: FAM labled SLN360 sodium
Research Areas:
FAM labled Zerlasiran sodium is a FAM labled Zerlasiran sodium (HY-147425A). Zerlasiran sodium is a siRNA targeting apolipoprotein A (ApoA). Zerlasiran sodium targets hepatic ApoA synthesis via RNA interference to degrade encoding mRNA. Zerlasiran sodium can be used for the research of atherosclerotic cardiovascular disease and elevated ApoA levels .
Cat. No.: HY-147425E
Synonyms: Cy3 labled SLN360 sodium
Research Areas:
Cy3 labled Zerlasiran sodium is a Cy3 labled Zerlasiran sodium (HY-147425A). Zerlasiran sodium is a siRNA targeting apolipoprotein A (ApoA). Zerlasiran sodium targets hepatic ApoA synthesis via RNA interference to degrade encoding mRNA. Zerlasiran sodium can be used for the research of atherosclerotic cardiovascular disease and elevated ApoA levels .
- 1
- 2
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
